

Latest Journal Citations for **esRAGE ELISA Kit (Cat.# K1009-1)** (Updated Nov. 2018)

[under **As One International** or **B-Bridge International**]

1. Miranda ER et al. [Endogenous secretory RAGE increases with improvements in body composition and is associated with markers of adipocyte health](#), *Nutrition, Metabolism and Cardiovascular Diseases*, **November 2018**, 28(11): 1155-1165. <https://doi.org/10.1016/j.numecd.2018.07.009>.
2. Ding B. et al. [Clinical relevance of cleaved RAGE plasma levels as a biomarker of disease severity and functional outcome in aneurysmal subarachnoid hemorrhage](#), *Clinica Chimica Acta*, **November 2018**, 486: 335-340. <https://doi.org/10.1016/j.cca.2018.08.036>.
3. Wu F et al. [Temporal reliability of serum soluble and endogenous secretory receptors for advanced glycation end-products \(sRAGE and esRAGE\) in healthy women](#). *Cancer Causes & Control*, **October 2018**, 29(10): 901-905. <https://doi.org/10.1007/s10552-018-1066-4>.
4. Kelly NZ et al. [A single high-fat meal alters human soluble RAGE profiles and PBMC RAGE expression with no effect of prior aerobic exercise](#). *Physiol Rep*, **July 2018**, 6(14), e13811, <https://doi.org/10.14814/phy2.13811>.
5. Roggerio A et al. [Gene Expression of Sirtuin-1 and Endogenous Secretory Receptor for Advanced Glycation End Products in Healthy and Slightly Overweight Subjects after Caloric Restriction and Resveratrol Administration](#). *Nutrients*, **July 2018**, 10(7): 937. <https://doi.org/10.3390/nu10070937>
6. Mehta R et al. [Polymorphisms in the receptor for advanced glycation end-products \(RAGE\) gene and circulating RAGE levels as a susceptibility factor for non-alcoholic steatohepatitis \(NASH\)](#). *PLoS ONE*, **June 2018**, 13(6): e0199294. <https://doi.org/10.1371/journal.pone.0199294>.
7. Kelesidis T et al. [Soluble levels of receptor for advanced glycation endproducts and dysfunctional high-density lipoprotein in persons infected with human immunodeficiency virus: ACTG NWCS332](#). *Medicine: June 2018*, 97(22): e10955. <https://doi.org/10.1097/MD.0000000000010955>.
8. Chen X et al. [Blockade of HMGB1 Attenuates Diabetic Nephropathy in Mice](#), *Scientific Reports*. **May 2018**, Volume 8, Article number: 8319. <https://doi.org/10.1038/s41598-018-26637-5>.
9. Pranal T et al. [Clinical and Biological Predictors of Plasma Levels of Soluble RAGE in Critically Ill Patients: Secondary Analysis of a Prospective Multicenter Observational Study](#). *Disease Markers*. **May 2018**, Vol. 2018, Article ID 7849675, 13 pages. <https://doi.org/10.1155/2018/7849675>.
10. Benjamin et al. [Inverse Relationship between Soluble RAGE and Risk for Bronchopulmonary Dysplasia](#). *Am J Respir Crit Care Med*. **April 2018**, 197(8): 1083-1086. <https://doi.org/10.1164/rccm.201707-1445LE>.
11. Yang G et al. [Endogenous Secretory Receptor for Advanced Glycation End Products Protects Endothelial Cells from AGEs Induced Apoptosis](#), *BioMed Research International*, **April 2018**, Article ID 8216578, 8 pages. <https://doi.org/10.1155/2018/8216578>
12. El-Far et al. [In vitro anticancer effects of a RAGE inhibitor discovered using a structure-based drug design system](#). *Oncology Letters*, **April 2018**, <https://doi.org/10.3892/ol.2018.7902>.
13. Sternberg et al. [Fingolimod anti-inflammatory and neuroprotective effects modulation of RAGE axis in multiple sclerosis patients](#). *Neuropharmacology*. **March 2018**, 130, 71-76. 9. <https://doi.org/10.1016/j.neuropharm.2017.11.047>.
14. Jabaudon M et al. [Receptor for advanced glycation end-products and ARDS prediction: a multicentre observational study](#). *Scientific Reports*. **February 2018**, Volume 8, Article number: 2603. <https://doi.org/10.1038/s41598-018-20994-x>.